HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Xeris Biopharma Holdings (NASDAQ:XERS) and maintained a $6 price target, as stated by analyst Oren Livnat.
May 31, 2024 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Xeris Biopharma Holdings and maintained a $6 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100